INCA 00186
Alternative Names: INCA 0186; INCA-00186Latest Information Update: 09 Aug 2023
At a glance
- Originator Incyte Corporation
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gastrointestinal cancer; Solid tumours; Squamous cell cancer
Most Recent Events
- 02 May 2023 Discontinued - Phase-I for Gastrointestinal cancer (Combination therapy, Second-line therapy or greater) in USA (Parenteral) prior to May 2023
- 02 May 2023 Discontinued - Phase-I for Gastrointestinal cancer (Monotherapy, Second-line therapy or greater) in USA (Parenteral) prior to May 2023
- 02 May 2023 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (Parenteral) prior to May 2023